ArticleAntimicrobial agents and chemotherapy2008
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
Article in Antimicrobial agents and chemotherapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 76 citations in OpenAlex.
- Clinical efficacy of intravenous doripenem in patients with acute biliary tract infection: a multicenter, randomized, controlled trial with imipenem/cilastatin as comparator.Journal of gastroenterology · 2015Trial
- Effect of Quinolone Prophylaxis Discontinuation During Pre-engraftment Neutropenia on Incidence, Mortality, and Etiology of Bloodstream Infections in Hematopoietic Stem-cell Transplant Recipients: A Systematic Review and Meta-analysis.Open forum infectious diseases · 2026Article
- Antibiotic Resistance inAntibiotics (Basel, Switzerland) · 2026Review
- Ciprofloxacin pre-exposure influences individual cell MIC and heteroresistance of bacteria inside microfluidic droplets.Scientific reports · 2025Article
- Pharmacokinetics of continuous infusion ceftolozane/tazobactam in two patients with extensive total body surface area burns.Pharmacotherapy · 2025Article
- Antimicrobial Resistance and Mortality in Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Mutational signature analysis predicts bacterial hypermutation and multidrug resistance.Nature communications · 2025Article
- Article
- The SOS Response Activation and the Risk of Antibiotic Resistance Enhancement inInternational journal of molecular sciences · 2024Article
- Use of the Hollow-Fiber Infection Model to Measure the Effect of Combination Therapy of Septic Shock Exposures of Meropenem and Ciprofloxacin against Intermediate and Resistant Pseudomonas aeruginosa Clinical Isolates.Antimicrobial agents and chemotherapy · 2022Article
- RecA and Specialized Error-Prone DNA Polymerases Are Not Required for Mutagenesis and Antibiotic Resistance Induced by Fluoroquinolones inAntibiotics (Basel, Switzerland) · 2022Article
- Case Report: Whole-Genome Sequencing of Serially CollectedFrontiers in cellular and infection microbiology · 2022Article
- Maximum levels of cross-contamination for 24 antimicrobial active substances in non-target feed. Part 10:EFSA journal. European Food Safety Authority · 2021Article
- Article
- The Pseudomonas aeruginosa substrate-binding protein Ttg2D functions as a general glycerophospholipid transporter across the periplasm.Communications biology · 2021Article
- Risk Factors for and Clinical Outcomes of Carbapenem-ResistantInfection and drug resistance · 2021Article
- Bacterial antibiotic resistance development and mutagenesis following exposure to subinhibitory concentrations of fluoroquinolonesJAC-antimicrobial resistance · 2020Review
- Issues beyond resistance: inadequate antibiotic therapy and bacterial hypervirulence.FEMS microbes · 2020Review
- Fluoroquinolone Prophylaxis Selects for Meropenem-nonsusceptible Pseudomonas aeruginosa in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- Risk Factors for Carbapenem-resistantChinese medical journal · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mutation frequency for carbapenem resistance in Pseudomonas aeruginosa strains that were selected with carbapenems was enhanced in the presence of subinhibitory concentrations of fluoroquinolones. The mutants showed either a loss of OprD activity or increased mexAB-oprM expression. The highest mutant isolation frequency was obtained by selection with meropenem, while doripenem inhibited mutant growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.